Skip to main content
See every side of every news story
Published • loading... • Updated

Exegenesis Licenses AAV Capsid for Duchenne Therapy Push

Summary by MyChesCo
HORSHAM, PA — Exegenesis Bio will supply its muscle-targeting AAV delivery technology to Modalis Therapeutics Corp. (TOKYO: 4883) under a research and licensing agreement aimed at advancing an experimental Duchenne …
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MyChesCo broke the news on Monday, September 21, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal